BriaCell Therapeutics Corp. (BCTXW)

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, operating in the cancer immunotherapy market where immunotherapies harness the body's own immune system to recognize and destroy cancer cells. The global market for cancer drugs, including immunotherapy drugs, is expected to reach nearly $467 billion by the end of 2030 ¹. Approximately 324,580 people (321,910 women and 2,670 men) are projected to be diagnosed with breast cancer in the United States in 2026 ², with more than 42,670 projected to die in 2026 ³. Approximately 13% of women will be diagnosed with breast cancer at some point during their lifetime ⁴, and in 2025 over 4 million women were living with breast cancer in the United States ⁵. Approximately 83% of cases present as invasive breast cancer ⁶, and approximately 6% of new breast cancer diagnoses are Stage IV metastatic breast cancer ⁷. Twenty to thirty percent of all women diagnosed with breast cancer will develop MBC ⁸. Based on the latest SEER statistics, 68% were found to be HR+/HER2−, 10% were triple-negative, 10% were HR+/HER2+, and 4% were HR−/HER2+ ⁹. The majority (64%) of breast cancers diagnosed in 2015-2021 were localized, while the remainder were either regional (28%), metastatic/distant (6%), or unknown (2%) ¹⁰. The 5-year relative survival rates for patients with localized, regional, or distant breast cancer are 100%, 87.2%, and 32.6%, respectively ¹¹. The number of women in the US living with MBC is projected to increase to over 240,000 by 2030 ¹². For patients with MBC who have received 2 or more prior lines of therapy, median survival is 5.9-9.8 months ¹³. Median progression free survival after first-line therapy is only 9 months ¹⁴. Of 386 patients with MBC, 374 (97%) received first-line therapy, 254 (66%) received second-line therapy, 175 (45%) received third-line therapy, and 105 (27%) received therapy beyond third-line ¹⁵.

BriaCell's lead candidate Bria-IMT™ is a whole-cell immunotherapy for metastatic breast cancer undergoing pivotal Phase 3 clinical testing in combination with an immune checkpoint inhibitor (Retifanlimab®) in patients with advanced MBC who have failed prior lines of therapy ¹⁶. Bria-IMT™ is currently under Fast Track Designation by the FDA intended to accelerate the review process of novel treatments that address unmet medical needs ¹⁷. Positive completion of the pivotal study, following review by FDA, could lead to full approval of the Bria-IMT™ immune checkpoint inhibitor combination in metastatic breast cancer ¹⁸. BriaCell has reported benchmark-beating patient survival and clinical benefit in metastatic breast cancer with median overall survival of 13.3 months for the Phase 3 sequence in BriaCell's metastatic breast cancer patients ¹⁹. Additionally, BriaCell reported median overall survival of 16.6 months in Phase 2 Bria-IMT™ study patients treated in combination with immune checkpoint inhibitor in patients treated with the Phase 3 formulation since 2022 ²⁰. The Phase 3 study is expected to enroll 177 patients in the Bria-IMT™ combination therapy arm and 177 patients in the treatment of physician's choice arm ²¹. To gather additional information on the Bria-IMT™ regimen alone, 50 patients are expected to be enrolled in this regimen ²². The first interim analysis will be at 144 events (mortalities) ²³. If the hazard ratio (HR) is ≤ 0.6, BriaCell will submit a Biologics License Application (BLA) ²⁴. If the HR is > 0.6, the study will continue to completion with HR target of 0.7 ²⁵. As of September 14, 2026, the DSMB had issued seven consecutive positive recommendations, in each case identifying no safety concerns and recommending continuation of the study ²⁶. On December 9, 2025, BriaCell announced that patient enrollment is on track for 1H2026 topline data readout with over 230 patients screened and over 160 patients enrolled in BriaCell's pivotal Phase 3 study in metastatic breast cancer ²⁷. On May 12, 2026, BriaCell announced that enrollment in the Bria-ABC pivotal breast cancer study had surpassed 230 patients ²⁸.

BriaCell is developing Bria-OTS™, a personalized off-the-shelf immunotherapy, and its advanced form, Bria-OTS+™, as a platform technology for personalized off-the-shelf immunotherapies for numerous types of cancer ²⁹. Bria-OTS™ is engineered to express 15 unique HLA types through 4 independent cell lines ³⁰, providing matched treatment to greater than 99% of patients ³¹. A simple saliva test provides HLA matching for personalized off-the-shelf Bria-OTS™ immunotherapy ³². The first patient treated with 4 inoculations of cells (single agent) demonstrated complete resolution of a lung metastasis ³³. BriaCell has received from the FDA permission to proceed with Phase 1/2a clinical studies of Bria-BRES+™ for breast cancer and Bria-PROS+™ for prostate cancer with open Investigational New Drug Applications (INDs) for both ³⁴. BriaCell recently announced progress in developing Bria-OVA+, its next generation, personalized, off-the-shelf, cell-based immunotherapy for ovarian cancer, and Bria-MEL+, its personalized whole cell melanoma immunotherapy vaccine candidate has achieved a key genetic engineering milestone advancing the program toward clinical development ³⁵. On May 28, 2024, BriaCell announced a clinical supply agreement with BeiGene for Bria-OTS™ first in human study ³⁶. This study will evaluate the effects of Bria-OTS™ in combination with anti-PD-1 antibody tislelizumab, in advanced, late stage, heavily pretreated metastatic breast cancer ³⁷.

BriaCell does not own or operate manufacturing facilities to produce its product candidates and currently depends on third-party contract manufacturers for all required raw materials, active pharmaceutical ingredients, and finished product candidate for clinical trials ³⁸. Bria-IMT™ is currently manufactured under current Good Manufacturing Practices (cGMP) pursuant to agreements with University of California, Davis (UC Davis) and with FujiFilm Diosynth Biotechnology (Fuji), which is located in Thousand Oaks, California ³⁹. Pursuant to the Company's master services agreement with Fuji, dated May 9, 2023, to manufacture Bria-IMT™, for anticipated use in clinical studies including the Phase 3 study ⁴⁰. On July 15, 2026, BriaCell announced a manufacturing arrangement with FUJIFILM Biotechnologies California, a leading contract development and manufacturing organization (CDMO) specializing in cell therapies, to support the ongoing pivotal Phase 3 clinical development and potential future commercial supply of BriaCell's lead clinical candidate, Bria-IMT ⁴¹. Bria-IMT™ cells grow in simple tissue culture media and are irradiated prior to inoculation ⁴². Fuji and the UC Davis GMP facility have developed a frozen formulation where the cells are grown, harvested and irradiated, followed by cryopreservation in a viable state ⁴³. The cells are stockpiled and shipped directly to clinical sites for inoculation ⁴⁴. Each lot of Bria-IMT™ is tested for potency (i.e. GM-CSF production), identity (i.e. HER2+ and ER/PR-) and adventitious agents to rule out contamination with infectious agents ⁴⁵. To date, there have been no issues with these tests ⁴⁶.

During the period from August 1, 2025, through to the date of this report, BriaCell announced a number of corporate, financing and R&D developments ⁴⁷. On August 13, 2025, BriaCell announced acceptance into Memorial Sloan Kettering Cancer Center's (MSK's) 2025 Therapeutics Accelerator Cohort program for the Bria-OTS+™ platform, which includes the Bria-BRES+™ product candidate for breast cancer ⁴⁸. On October 21, 2025, BriaCell announced a related collaboration with MSK's Therapeutics Accelerator program that includes support for manufacturing, IND development and clinical protocol work for a planned Phase 1 study of Bria-BRES+ in breast cancer ⁴⁹. On August 25, 2025, BriaCell reported that it had been awarded a US$2.0 million Small Business Innovation Research (SBIR) grant from the U.S. National Cancer Institute (NCI) to advance Bria-PROS+™ in prostate cancer, providing non-dilutive funding to support manufacturing and planned clinical evaluation activities for this program ⁵⁰. On June 25, 2026, BriaCell announced that it has entered into a Memorandum of Understanding (MoU), with Uneedle, a microneedle based drug-delivery device company in the Netherlands, to support the continued use and commercial readiness of Uneedle's proprietary microneedle technology for intradermal administration of BriaCell's lead Phase 3 clinical candidate, Bria-IMT, for the treatment of metastatic breast cancer ⁵¹. On July 7, 2026, BriaCell announced that it has engaged Charles River Associates (CRA) (Nasdaq: CRAI) and Kaleio, Inc. to support commercial strategy, market access evaluation and brand planning for Bria-IMT ⁵². On July 16, 2026, BriaCell announced that the Odette Cancer Centre at Sunnybrook Health Sciences Centre, a leading cancer center in Toronto, Ontario, Canada, has joined BriaCell's ongoing pivotal Phase 3 study of Bria-IMT plus an immune checkpoint inhibitor in metastatic breast cancer ⁵³. On September 8, 2026, BriaCell announced that Memorial Sloan Kettering Cancer Center (MSK) has joined BriaCell's ongoing pivotal Phase 3 study of Bria-IMT™ plus an immune checkpoint inhibitor in metastatic breast cancer ⁵⁴.

BriaCell is a pre-revenue clinical stage company ⁵⁵. The Company has reported no revenue for the fiscal year ended July 31, 2026 ⁵⁶. Net loss for the fiscal year ended July 31, 2026 was $23.486 million ⁵⁷, compared to a net loss of $28.9 million for the fiscal year ended July 31, 2025 ⁵⁸. Research and development expenses were $12.4 million for the fiscal year ended July 31, 2026 ⁵⁹, compared to $14.5 million for the fiscal year ended July 31, 2025 ⁶⁰. General and administrative expenses were $10.9 million for the fiscal year ended July 31, 2026 ⁶¹, compared to $14.4 million for the fiscal year ended July 31, 2025 ⁶². As of July 31, 2026, the Company had cash and cash equivalents of $8.9 million ⁶³ and short-term investments of $2.1 million ⁶⁴. The Company had an accumulated deficit of $147.5 million as of July 31, 2026 ⁶⁵. There is substantial doubt about the Company's ability to continue as a going concern ⁶⁶.

BriaCell's pivotal Phase 3 study of Bria-IMT™ in combination with an immune checkpoint inhibitor in advanced metastatic breast cancer is expected to enroll 177 patients in the Bria-IMT™ combination therapy arm and 177 patients in the treatment of physician's choice arm ⁶⁷. To gather additional information on the Bria-IMT™ regimen alone, 50 patients are expected to be enrolled in this regimen and will be eligible for combination therapy following their initial post treatment evaluation ⁶⁸. The first interim analysis will be at 144 events (mortalities) ⁶⁹. If the hazard ratio (HR) is ≤ 0.6, BriaCell will submit a Biologics License Application (BLA) ⁷⁰. If the HR is > 0.6, the study will continue to completion with HR target of 0.7 ⁷¹. Either of these could result in full approval of the Bria-IMT™ CPI combination regimen in advanced metastatic breast cancer ⁷². On December 9, 2025, BriaCell announced that patient enrollment is on track for 1H2026 topline data readout with over 230 patients screened and over 160 patients enrolled in BriaCell's pivotal Phase 3 study in metastatic breast cancer ⁷³. On May 12, 2026, BriaCell announced that enrollment in the Bria-ABC pivotal breast cancer study had surpassed 230 patients ⁷⁴.

BriaCell is developing Bria-OTS™, a personalized off-the-shelf immunotherapy, and its advanced form, Bria-OTS+™, as a platform technology for personalized off-the-shelf immunotherapies for numerous types of cancer ⁷⁵. Bria-OTS™ is engineered to express 15 unique HLA types through 4 independent cell lines ⁷⁶, providing matched treatment to greater than 99% of patients ⁷⁷. A simple saliva test provides HLA matching for personalized off-the-shelf Bria-OTS™ immunotherapy ⁷⁸. HLA matched off-the-shelf therapy is faster and less costly than other expensive and complex personalized immunotherapies ⁷⁹. BriaCell announced that the first patient treated with the Bria-OTS™ cells had a complete resolution of a breast cancer tumor that had metastasized to the lung ⁸⁰. This response was sustained at the 6 month timepoint ⁸¹. BriaCell has filed numerous US and international patents for Bria-OTS™ ⁸². On May 28, 2024, BriaCell announced a clinical supply agreement with BeiGene for Bria-OTS™ first in human study ⁸³. This study will evaluate the effects of Bria-OTS™ in combination with anti-PD-1 antibody tislelizumab, in advanced, late stage, heavily pretreated metastatic breast cancer ⁸⁴. An enhanced version (expressing also co-stimulatory molecules and cytokines) termed Bria-OTS+™ is in development for prostate cancer (Bria-PROS+™), lung cancer (Bria-LUNG+™), and melanoma (Bria-MEL+™) as well as breast cancer (Bria-BRES+™) ⁸⁵. In September 2024, BriaCell announced positive pre-IND meeting with FDA for Bria-PROS+™ for prostate cancer ⁸⁶. BriaCell received a Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI) to further develop Bria-OTS+™ ⁸⁷. FDA has cleared INDs for Bria-BRES+™ (May 2026) and Bria-PROS+™ (August 2026) ⁸⁸.

On August 25, 2025, BriaCell reported that it had been awarded a US$2.0 million Small Business Innovation Research (SBIR) grant from the U.S. National Cancer Institute (NCI) to advance Bria-PROS+™ in prostate cancer, providing non-dilutive funding to support manufacturing and planned clinical evaluation activities for this program ⁸⁹. On August 13, 2025, BriaCell announced acceptance into Memorial Sloan Kettering Cancer Center's (MSK's) 2025 Therapeutics Accelerator Cohort program for the Bria-OTS+™ platform, which includes the Bria-BRES+™ product candidate for breast cancer ⁹⁰. On October 21, 2025, BriaCell announced a related collaboration with MSK's Therapeutics Accelerator program that includes support for manufacturing, IND development and clinical protocol work for a planned Phase 1 study of Bria-BRES+ in breast cancer ⁹¹. On June 25, 2026, BriaCell announced that it has entered into a Memorandum of Understanding (MoU), with Uneedle, a microneedle based drug-delivery device company in the Netherlands, to support the continued use and commercial readiness of Uneedle's proprietary microneedle technology for intradermal administration of BriaCell's lead Phase 3 clinical candidate, Bria-IMT, for the treatment of metastatic breast cancer ⁹². On July 7, 2026, BriaCell announced that it has engaged Charles River Associates (CRA) (Nasdaq: CRAI) and Kaleio, Inc. to support commercial strategy, market access evaluation and brand planning for Bria-IMT ⁹³. Charles River Associates (CRA) was engaged to evaluate epidemiology, pricing, prescriber dynamics, and market access potential for Bria-IMT in metastatic breast cancer in the US ⁹⁴. Kaleio was engaged to support brand strategies and customized commercial-readiness solutions ⁹⁵.

BriaCell does not own or operate manufacturing facilities to produce its product candidates and currently depends on third-party contract manufacturers for all required raw materials, active pharmaceutical ingredients, and finished product candidate for clinical trials ⁹⁶. Bria-IMT™ is currently manufactured under current Good Manufacturing Practices (cGMP) pursuant to agreements with University of California, Davis (UC Davis) and with FujiFilm Diosynth Biotechnology (Fuji), which is located in Thousand Oaks, California ⁹⁷. Pursuant to the Company's master services agreement with Fuji, dated May 9, 2023, to manufacture Bria-IMT™, for anticipated use in clinical studies including the Phase 3 study ⁹⁸. On July 15, 2026, BriaCell announced a manufacturing arrangement with FUJIFILM Biotechnologies California, a leading contract development and manufacturing organization (CDMO) specializing in cell therapies, to support the ongoing pivotal Phase 3 clinical development and potential future commercial supply of BriaCell's lead clinical candidate, Bria-IMT ⁹⁹. Bria-IMT™ cells grow in simple tissue culture media and are irradiated prior to inoculation ¹⁰⁰. Fuji and the UC Davis GMP facility have developed a frozen formulation where the cells are grown, harvested and irradiated, followed by cryopreservation in a viable state ¹⁰¹. The cells are stockpiled and shipped directly to clinical sites for inoculation ¹⁰². Each lot of Bria-IMT™ is tested for potency (i.e. GM-CSF production), identity (i.e. HER2+ and ER/PR-) and adventitious agents to rule out contamination with infectious agents ¹⁰³. To date, there have been no issues with these tests ¹⁰⁴.

BriaCell is a pre-revenue clinical stage company ¹⁰⁵. The Company has reported no revenue for the fiscal year ended July 31, 2026 ¹⁰⁶. Net loss for the fiscal year ended July 31, 2026 was $23.486 million ¹⁰⁷, compared to a net loss of $28.9 million for the fiscal year ended July 31, 2025 ¹⁰⁸. Research and development expenses were $12.4 million for the fiscal year ended July 31, 2026 ¹⁰⁹, compared to $14.5 million for the fiscal year ended July 31, 2025 ¹¹⁰. General and administrative expenses were $10.9 million for the fiscal year ended July 31, 2026 ¹¹¹, compared to $14.4 million for the fiscal year ended July 31, 2025 ¹¹². As of July 31, 2026, the Company had cash and cash equivalents of $8.9 million ¹¹³ and short-term investments of $2.1 million ¹¹⁴. The Company had an accumulated deficit of $147.5 million as of July 31, 2026 ¹¹⁵. There is substantial doubt about the Company's ability to continue as a going concern ¹¹⁶.

BriaCell has funded its operations primarily through the issuance of common shares and warrants ¹¹⁷. During the fiscal year ended July 31, 2026, the Company completed several financings ¹¹⁸. On January 15, 2026, BriaCell completed a public offering of common shares and pre-funded warrants ¹¹⁹. On June 2, 2026, BriaCell completed a public offering of common shares and warrants ¹²⁰. The Company has no dividend policy and has never paid cash dividends on its common shares ¹²¹. BriaCell expects to continue to incur significant expenses and increasing operating losses for the foreseeable future ¹²². The Company will need to raise substantial additional capital to fund its operations and complete the development and commercialization of its product candidates ¹²³.

Management's message to shareholders emphasizes the advancement of BriaCell's lead candidate Bria-IMT™ through its pivotal Phase 3 study in metastatic breast cancer, with patient enrollment on track for 1H2026 topline data readout with over 230 patients screened and over 160 patients enrolled ¹⁴². The Company has reported benchmark-beating patient survival and clinical benefit in metastatic breast cancer with median overall survival of 13.3 months for the Phase 3 sequence in BriaCell's metastatic breast cancer patients ¹⁴³, and median overall survival of 16.6 months in Phase 2 Bria-IMT™ study patients treated in combination with immune checkpoint inhibitor in patients treated with the Phase 3 formulation since 2022 ¹⁴⁴. Management highlights the independent Data Safety Monitoring Board's seven consecutive positive recommendations, in each case identifying no safety concerns and recommending continuation of the study ¹⁴⁵. Strategic priorities include advancing the Bria-OTS™ platform, with the first patient treated with 4 inoculations of cells (single agent) demonstrating complete resolution of a lung metastasis ¹⁴⁶, and expanding the pipeline with Bria-BRES+™ for breast cancer and Bria-PROS+™ for prostate cancer, for which the FDA has cleared INDs ¹⁴⁷. Management also emphasizes strengthening non-dilutive funding and external collaborations, including a US$2.0 million Small Business Innovation Research (SBIR) grant from the U.S. National Cancer Institute (NCI) to advance Bria-PROS+™ in prostate cancer ¹⁴⁸, and collaborations with Memorial Sloan Kettering Cancer Center's Therapeutics Accelerator program ¹⁴⁹.

BriaCell is a pre-revenue clinical stage company ¹⁵⁰. The Company has reported no revenue for the fiscal year ended July 31, 2026 ¹⁵¹ and no revenue for the fiscal year ended July 31, 2025 ¹⁵². Net loss for the fiscal year ended July 31, 2026 was $23.486 million ¹⁵³, compared to a net loss of $28.9 million for the fiscal year ended July 31, 2025 ¹⁵⁴. Net loss per share for the fiscal year ended July 31, 2026 was $2.73 ¹⁵⁵, compared to a net loss per share of $2.41 for the fiscal year ended July 31, 2025 ¹⁵⁶. Research and development expenses were $12.4 million for the fiscal year ended July 31, 2026 ¹⁵⁷, compared to $14.5 million for the fiscal year ended July 31, 2025 ¹⁵⁸. General and administrative expenses were $10.9 million for the fiscal year ended July 31, 2026 ¹⁵⁹, compared to $14.4 million for the fiscal year ended July 31, 2025 ¹⁶⁰. As of July 31, 2026, the Company had cash and cash equivalents of $8.9 million ¹⁶¹ and short-term investments of $2.1 million ¹⁶². The Company had an accumulated deficit of $147.5 million as of July 31, 2026 ¹⁶³. There is substantial doubt about the Company's ability to continue as a going concern ¹⁶⁴.

BriaCell faces substantial doubt about its ability to continue as a going concern ¹²⁴. The Company is a pre-revenue clinical stage company ¹²⁵ and has reported no revenue for the fiscal year ended July 31, 2026 ¹²⁶. Net loss for the fiscal year ended July 31, 2026 was $23.486 million ¹²⁷, and the Company had an accumulated deficit of $147.5 million as of July 31, 2026 ¹²⁸. As of July 31, 2026, the Company had cash and cash equivalents of $8.9 million ¹²⁹ and short-term investments of $2.1 million ¹³⁰. The Company will need to raise substantial additional capital to fund its operations and complete the development and commercialization of its product candidates ¹³¹. Pre-clinical studies and initial clinical trials are not predictive of future results ¹³². The Company is reliant on third-parties to carry out a portion of its business ¹³³. The Company is developing novel technologies which may not be effective or safe ¹³⁴. The Company may not successfully develop, maintain and protect its proprietary products and technologies ¹³⁵. Although BriaCell is not currently aware of any generic cell therapies, if the FDA or comparable foreign regulatory authorities approve generic versions of any of the Company's products that receive marketing approval, or such authorities do not grant the Company's products appropriate periods of exclusivity before approving generic versions of the Company's products, the sales of the Company's products could be adversely affected ¹³⁶. Changes in legislation and regulations may affect the Company's ability to generate revenue and profitability ¹³⁷. The Company is dependent on its key personnel ¹³⁸. The Company has an unproven market for its product candidates ¹³⁹. Short sellers may be manipulative and may drive down the market price of the Company's common shares ¹⁴⁰. Future issuance of the Company's common shares could dilute the interests of existing shareholders ¹⁴¹.